Chronic Inducible Urticaria, Subtype & Management

Diagnosis and management of chronic inducible urticaria (CIndU), wheals reproducibly triggered by a specific physical or environmental stimulus (dermographism, cold, cholinergic/heat, delayed pressure, solar, vibratory, aquagenic). Confirms the inducible subtype by provocation testing, separates it from chronic spontaneous urticaria, and applies the urticaria treatment ladder: standard then up-dosed second-generation H1 antihistamines, then omalizumab. Flags the anaphylaxis risk of cold and cholinergic urticaria.

Evidence tier: Guideline-derived.

Decision points

  • Inducible (physical) trigger, or spontaneous urticaria?
  • Controlled on standard-dose H1 antihistamine?

Do-not-miss pitfalls

  • Confirm the CIndU subtype with provocation testing, it both establishes the diagnosis and defines the trigger threshold for counseling. Empiric labeling without provocation misses overlap and mis-sets avoidance advice.
  • Cold urticaria and cholinergic urticaria can cause anaphylaxis (cold-water immersion, vigorous exercise/overheating), prescribe self-injectable epinephrine and give specific avoidance counseling regardless of antihistamine response.
  • The treatment ladder is the same as CSU: standard-dose second-generation H1 antihistamine → up-dose up to fourfold → omalizumab → cyclosporine. Do not jump to systemic steroids for maintenance.
  • Up-dosing the antihistamine (up to 4×) is guideline-endorsed and preferred over adding a first-generation sedating antihistamine, which causes sedation and impairs performance without better control.
  • Omalizumab is effective across inducible subtypes (symptomatic dermographism, cold, solar, cholinergic), not just spontaneous urticaria, use it for antihistamine-refractory CIndU.
  • Delayed pressure urticaria appears hours after sustained pressure and responds less well to antihistamines, it may need omalizumab or other escalation, and is easily missed because of the delay.
  • CIndU and CSU frequently coexist, a positive provocation test does not exclude a spontaneous component; treat both if present.
  • Avoid long-term oral corticosteroids, they are not a maintenance strategy for urticaria and cause cumulative harm; escalate along the ladder instead.

Evidence & citations

  1. Magerl M, Altrichter S, Borzova E, et al. The definition, diagnostic testing, and management of chronic inducible urticarias, The EAACI/GA²LEN/EDF/UNEV consensus recommendations 2016 update and revision. Allergy. 2016;71(6):780-802. PMID 26991006
  2. Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734-766. PMID 34536239
  3. Saini SS, Bindslev-Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol. 2015;135(1):67-75. PMID 25046337

Clinician decision support. Verify against the cited source. Not a substitute for clinical judgment. 100% on-device; no patient data is stored or transmitted.